The global hepatitis C drug market was valued at USD 7.86 billion in 2018 and is expected to grow to USD 9.84 billion by 2032, registering a compound annual growth rate (CAGR) of 1.8% over the forecast period from 2018 to 2032. In 2018, North America led the market, accounting for 47.46% of the global share.

The Hepatitis C drug market is witnessing steady growth due to increasing awareness, rising diagnosis rates, and advancements in antiviral therapies. The market is primarily driven by the widespread adoption of direct-acting antiviral (DAA) drugs, which offer high cure rates, fewer side effects, and shorter treatment durations. Government initiatives, public health campaigns, and expanded screening programs are also contributing to market expansion, especially in developing regions. As patents for several branded drugs expire, the entry of cost-effective generics is expected to boost accessibility and treatment uptake. With continued innovation and global efforts to eliminate Hepatitis C, the market is poised for sustained development over the coming years.

Continue reading for more details:

**https://www.fortunebusinessinsights.com/industry-reports/hepatitis-c-drug-market-101562**

Market Segmentation

• The Hepatitis C drug market is segmented based on drug class into direct-acting antivirals, combination therapies, and others.
• By distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies.
• Patient type segmentation includes acute and chronic hepatitis C cases, with chronic infections accounting for the majority of the demand.
• The Hepatitis C drug market also segments drugs based on genotypes, with pan-genotypic regimens becoming increasingly dominant.

List of Companies Profiled:

• AbbVie Inc.
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Janssen Pharmaceuticals, Inc.
• Merck Sharp & Dohme Corp.
• F. Hoffmann-La Roche Ltd
• Vertex Pharmaceuticals Incorporated
• Other Prominent Players